Berek JS - Search Results

1

Progress in the management of gynecologic cancer: consensus summary statement.

Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Cannistra SA, et al. Among authors: berek js. J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. doi: 10.1200/JCO.2003.04.003. J Clin Oncol. 2003. PMID: 12743127 No abstract available.

2

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.

Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Markman M, et al. Among authors: berek js. Gynecol Oncol. 1992 Apr;45(1):3-8. doi: 10.1016/0090-8258(92)90482-x. Gynecol Oncol. 1992. PMID: 1601332 Clinical Trial.

3

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study.

McGuire WP 3rd, Blessing JA, Berek JS, Munoz A. McGuire WP 3rd, et al. Among authors: berek js. Invest New Drugs. 1990 May;8(2):191-4. doi: 10.1007/BF00177257. Invest New Drugs. 1990. PMID: 2384305

4

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.

McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. McGuire WP, et al. Among authors: berek js. J Clin Oncol. 1995 Jul;13(7):1589-99. doi: 10.1200/JCO.1995.13.7.1589. J Clin Oncol. 1995. PMID: 7602348 Clinical Trial.

5

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. Hoskins WJ, et al. Among authors: berek js. Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80. doi: 10.1016/s0002-9378(94)70090-7. Am J Obstet Gynecol. 1994. PMID: 8166218 Clinical Trial.

6

Advanced ovarian cancer. Tumour markers.

Rustin GJ, van der Burg ME, Berek JS. Rustin GJ, et al. Among authors: berek js. Ann Oncol. 1993;4 Suppl 4:71-7. Ann Oncol. 1993. PMID: 8312203 Review.

7

Molecular and biological factors in the pathogenesis of ovarian cancer.

Berek JS, Martínez-Maza O, Hamilton T, Tropé C, Kaern J, Baak J, Rustin GJ. Berek JS, et al. Ann Oncol. 1993;4 Suppl 4:3-16. doi: 10.1093/annonc/4.suppl_4.s3. Ann Oncol. 1993. PMID: 8312207 Review.

8

Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.

Berek JS, Bast RC Jr. Berek JS, et al. Cancer. 1995 Nov 15;76(10 Suppl):2092-6. doi: 10.1002/1097-0142(19951115)76:10+<2092::aid-cncr2820761331>3.0.co;2-t. Cancer. 1995. PMID: 8635006 Review.

9

Advanced epithelial ovarian cancer: 1998 consensus statements.

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al. Berek JS, et al. Ann Oncol. 1999;10 Suppl 1:87-92. doi: 10.1023/a:1008323922057. Ann Oncol. 1999. PMID: 10219460

10

Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.

Berek JS, Markman M, Blessing JA, Kucera PR, Nelson BE, Anderson B, Hanjani P. Berek JS, et al. Gynecol Oncol. 1999 Jul;74(1):48-52. doi: 10.1006/gyno.1999.5455. Gynecol Oncol. 1999. PMID: 10385550 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

313 results

Search Page